Caspofungin for Pneumocystis Pneumonia in HIV patients
Part of Infections, Lungs & breathing clinical trials.
This trial tests caspofungin, a medicine, for treating Pneumocystis pneumonia (PCP) in people living with HIV. It aims to see if it works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of Pneumocystis pneumonia (PCP) that is either proven or probable based on specific medical criteria.
- You must have had lab tests (both clinical and virological) done when you were admitted to the hospital.
- You cannot have had your treatment changed to caspofungin after 7 days of starting therapy (this only applies if you are in group B).
- You must not have developed another lung infection during your hospital stay, except for certain infections like cytomegalovirus or COVID-19.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled version of the drug caspofungin as an add-on treatment for people with severe Pneumocystis pneumonia. It aims to see if breathing in the drug can help fight the infection better than the standard treatment alone.
This Phase 2 trial tests rezafungin, an antifungal medicine, to treat Pneumocystis pneumonia (PCP) in adults living with HIV. It may help people recover faster or more effectively from this serious lung infection.
This Phase 3 study tests whether low-dose trimethoprim-sulfamethoxazole (also called TMP-SMX) can treat Pneumocystis pneumonia (PCP) in people with weakened immune systems. It may help improve treatment while reducing side effects compared with standard dosing.
This trial is testing whether a shorter or longer course of steroids works better for people recovering from severe Pneumocystis pneumonia (a lung infection). If you are 18 or older and have been on steroids for about 10 days but no longer need extra oxygen, you may be able to join.
This study tests whether short-term steroid treatment helps adults with a specific lung infection (PCP) that happens with HIV/AIDS. It compares outcomes in people who start steroids soon after admission while also taking standard PCP antibiotics.
This trial tests different antibiotics for people with pneumocystis pneumonia who cannot take the standard treatment. It aims to find the best alternative therapy.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.